Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 09 Feb 2017 Primary endpoint (Percentage change from baseline tumor size at Week 12) has been met, according to an ASLAN Pharmaceuticals Media Release.
- 09 Feb 2017 Positive top-line results (n=50) published in an ASLAN Pharmaceuticals Media Release.
- 11 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History